Dr. Gary D'Souza
Gary D’Souza, PhD, is a senior scientist at Melior Discovery. He has over 10 years of research experience in immunology, neuroscience, pharmacology, and cell and molecular biology.
Dr. D’Souza received his PhD from the University of Auckland, New Zealand, investigating the safety and efficacy of a repurposed smoking cessation drug as a potential therapy for dysfunctional cholinergic transmission in Huntington’s disease. During his 4-year PhD, Dr. D’Souza took the drug from proof-of-concept animal studies to a small-scale, exploratory clinical study. He subsequently conducted postdoctoral training at the Biodesign Institute in Tempe, AZ, where he investigated the ability of a repurposed oncology drug to modulate neuroinflammation and amyloidogenesis in Alzheimer’s disease. Dr. D’Souza continued his postdoctoral training at Rush University Medical Center in Chicago, IL, where he took a systems neuroscience approach to diverse projects ranging from exploring changes in synaptic transmission after cocaine withdrawal to investigating aberrant calcium signaling in cognitive aging.
Over his research career, Dr. D’Souza has gained familiarity with inducible and genetic rodent models of inflammation, spinal cord injury, aging and neurodegenerative disease, and has extensive experience with all aspects of in vivo studies, including husbandry, genotyping, rodent surgery, behavioral studies, aseptic drug administration, perfusion, blood and tissue collection, and dissection. He also has expertise in numerous in vitro techniques including cell/tissue culture, cell and molecular biology based-assays, HPLC and microscopy. Further, Dr. D’Souza is also proficient in data analysis and interpretation, results-oriented project management, as well as clear and concise written and oral communication for scientific and non-scientific audiences.
Dr. D’Souza has a passion for preclinical drug development, and prides himself on his creative problem-solving, adaptability and attention to detail.